Search

Introduction: Subcutaneous atezolizumab is approved for the treatment of various solid tumors. Previous results from the IMscin001 study (NCT03735121) revealed that the pharmacokinetics, efficacy, immunogenicity, and safety of subcutaneous and intravenous atezolizumab were consistent (data cutoff: April 26, 2022). We present updated data from this trial (data cutoff: January 16, 2023)., Methods: Eligible patients aged above or equal to 18 years with locally advanced or metastatic NSCLC were randomized (2:1) to receive atezolizumab subcutaneously (1875 mg, n = 247) or intravenously (1200 mg, n = 124) every 3 weeks. Here, we present updated efficacy (overall survival [OS]; progression-free survival; objective response rate; duration of response), safety, and immunogenicity end points, alongside patient-reported outcomes and health care practitioner (HCP) perspectives., Results: In this updated analysis, the median survival follow-up was 9.5 months. Median subcutaneous injection time was 7.1 minutes, with an average subcutaneous injection time of 4 to 8 minutes in most patients (75.7%). OS data were mature: median OS was similar between treatment arms, at 10.7 and 10.1 months in the subcutaneous and intravenous arms, respectively (hazard ratio: 0.88; 95% confidence interval: 0.67-1.16). Other efficacy end points, as well as immunogenicity, patient-reported outcomes, and safety, were similar between arms. Most HCPs found subcutaneous administration convenient (79.5%), easy to administer (89.7%), and were satisfied with the treatment (84.6%); 75.0% of HCPs agreed that administering atezolizumab subcutaneously compared with intravenously could save time., Conclusions: In this analysis, mature OS data were similar between treatments. The updated efficacy and safety profile of subcutaneous atezolizumab is consistent with previous findings and equivalent to intravenous atezolizumab., Competing Interests: Disclosure Dr. Burotto received honoraria or consulting fees from and has served on advisory boards for AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., and Merck Sharp & Dohme. Dr. Zvirbule received honoraria from AstraZeneca and travel support for attending meetings from F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme, and AstraZeneca. Dr. Chewaskulyong received honoraria or consulting fees from F. Hoffmann-La Roche Ltd. and has had a leadership or fiduciary role in other board, society, committee, or advocacy group for F. Hoffmann-La Roche Ltd. Dr. Herraez-Baranda is employed full time at F. Hoffmann-La Roche Ltd. and has stocks or shares in F. Hoffmann-La Roche Ltd. Dr. Shearer-Kang is employed full time at Genentech and has stocks or shares in F. Hoffmann-La Roche Ltd. Dr. Liu is employed full time at Genentech and has stocks or shares in F. Hoffmann-La Roche Ltd. Dr. Tosti is employed full time at F. Hoffmann-La Roche Ltd. and has stocks or shares in F. Hoffmann-La Roche Ltd. Dr. Williams is employed full time at Genentech and has stocks or shares in F. Hoffmann-La Roche Ltd. Dr. Castro Sanchez is employed full time at F. Hoffmann-La Roche Ltd. and has stocks or shares in F. Hoffmann-La Roche Ltd. Dr. Zanghi is employed full time at Genentech and has stocks or shares in F. Hoffmann-La Roche Ltd. Dr. Felip received honoraria or consulting fees from and has served on advisory boards for AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Ipsen, Janssen, Medical Trends, Medscape, Merck KGaA, Merck Sharp & Dohme, Novartis, PeerVoice, Peptomyc, Pfizer, Sanofi, Takeda, Touch Oncology, and Turning Point; received travel support for attending meetings from AstraZeneca, Janssen, and F. Hoffmann-La Roche Ltd.; and is an independent member of the board for Grifols. Dr. Alvarez declares no conflict of interest., (Copyright © 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)